Yes, Avtozma (tocilizumab-anoh) is equivalent to Actemra (tocilizumab)
Biosimilars are considered equivalent to FDA-approved originator biologic DMARDs according to current rheumatology guidelines 1. This principle applies directly to Avtozma and Actemra.
Regulatory and Clinical Equivalence
The 2021 American College of Rheumatology guidelines explicitly state in their guiding principles that "biosimilars are considered equivalent to FDA-approved originator bDMARDs" 1. This represents the highest-level guidance available and directly addresses your question.
The EULAR recommendations similarly acknowledge biosimilars, noting that biosimilar agents (such as CT-P13 for infliximab) demonstrate similar efficacy and safety profiles to original antibodies in rheumatoid arthritis 2.
Supporting Evidence from Research
Recent meta-analyses confirm this equivalence:
Pharmacokinetic biosimilarity: Tocilizumab biosimilars demonstrate PK equivalence with pooled geometric mean ratios entirely within the 80-125% regulatory acceptance range for AUC and Cmax parameters 3
Clinical efficacy: No significant differences exist between biosimilars and reference tocilizumab for ACR20/50/70 responses or DAS28-ESR changes at 12 and 24 weeks 3, 4
Safety profile: Comparable adverse event rates, serious adverse events, and anti-drug antibody positivity between biosimilars and reference product 3, 4
Structural similarity: Biosimilar candidates show identical amino acid sequences, similar glycosylation patterns, comparable secondary/tertiary structures, and equivalent IL-6 receptor binding 5
Clinical Implications
You can prescribe or switch to Avtozma with confidence that:
- Efficacy will be maintained: Clinical response rates (ACR criteria, DAS28 scores) are therapeutically equivalent
- Safety profile is comparable: No increased risk of infections, immunogenicity, or other adverse events
- Dosing remains identical: Use the same weight-based or fixed dosing as reference tocilizumab
- Monitoring is unchanged: Continue standard laboratory monitoring for neutropenia, thrombocytopenia, and liver function
Important Caveats
While biosimilars are equivalent to the originator:
- Do not switch between different biosimilars and the originator multiple times without clinical justification - maintain consistency when possible to facilitate adverse event tracking
- Document the specific product name (Avtozma vs Actemra) in medical records for pharmacovigilance purposes
- If a patient fails one tocilizumab product, switching to another tocilizumab biosimilar is not considered "switching to another mechanism of action" - this would be analogous to switching between different infliximab products 2
The cost savings from biosimilars like Avtozma can improve access to IL-6 inhibitor therapy without compromising clinical outcomes, which is particularly relevant given tocilizumab's established efficacy in moderate-to-severe rheumatoid arthritis 6.